BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability
Blood vessel epicardial substance (BVES), or POPDC1, is a tight junction-associated transmembrane protein that modulates epithelial-to-mesenchymal transition (EMT) via junctional signaling pathways. There have been no in vivo studies investigating the role of BVES in colitis. We hypothesized that BVES is critical for maintaining colonic epithelial integrity. At baseline, Bves-/- mouse colons demonstrate increased crypt height, elevated proliferation, decreased apoptosis, altered intestinal lineage allocation, and dysregulation of tight junctions with functional deficits in permeability and altered intestinal immunity. Bves-/- mice inoculated with Citrobacter rodentium had greater colonic injury, increased colonic and mesenteric lymph node bacterial colonization, and altered immune responses after infection. We propose that increased bacterial colonization and translocation result in amplified immune responses and worsened injury. Similarly, dextran sodium sulfate (DSS) treatment resulted in greater histologic injury in Bves-/- mice. Two different human cell lines (Caco2 and HEK293Ts) co-cultured with enteropathogenic E. coli showed increased attaching/effacing lesions in the absence of BVES. Finally, BVES mRNA levels were reduced in human ulcerative colitis (UC) biopsy specimens. Collectively, these studies suggest that BVES plays a protective role both in ulcerative and infectious colitis and identify BVES as a critical protector of colonic mucosal integrity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Mucosal immunology - 11(2018), 5 vom: 15. Sept., Seite 1363-1374 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choksi, Yash A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.07.2019 Date Revised 31.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41385-018-0043-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285520857 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285520857 | ||
| 003 | DE-627 | ||
| 005 | 20231225045625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41385-018-0043-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0951.xml |
| 035 | |a (DE-627)NLM285520857 | ||
| 035 | |a (NLM)29907869 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choksi, Yash A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2019 | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Blood vessel epicardial substance (BVES), or POPDC1, is a tight junction-associated transmembrane protein that modulates epithelial-to-mesenchymal transition (EMT) via junctional signaling pathways. There have been no in vivo studies investigating the role of BVES in colitis. We hypothesized that BVES is critical for maintaining colonic epithelial integrity. At baseline, Bves-/- mouse colons demonstrate increased crypt height, elevated proliferation, decreased apoptosis, altered intestinal lineage allocation, and dysregulation of tight junctions with functional deficits in permeability and altered intestinal immunity. Bves-/- mice inoculated with Citrobacter rodentium had greater colonic injury, increased colonic and mesenteric lymph node bacterial colonization, and altered immune responses after infection. We propose that increased bacterial colonization and translocation result in amplified immune responses and worsened injury. Similarly, dextran sodium sulfate (DSS) treatment resulted in greater histologic injury in Bves-/- mice. Two different human cell lines (Caco2 and HEK293Ts) co-cultured with enteropathogenic E. coli showed increased attaching/effacing lesions in the absence of BVES. Finally, BVES mRNA levels were reduced in human ulcerative colitis (UC) biopsy specimens. Collectively, these studies suggest that BVES plays a protective role both in ulcerative and infectious colitis and identify BVES as a critical protector of colonic mucosal integrity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a BVES protein, human |2 NLM | |
| 650 | 7 | |a Cell Adhesion Molecules |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Muscle Proteins |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Dextran Sulfate |2 NLM | |
| 650 | 7 | |a 9042-14-2 |2 NLM | |
| 700 | 1 | |a Reddy, Vishruth K |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Kshipra |e verfasserin |4 aut | |
| 700 | 1 | |a Barrett, Caitlyn W |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Sarah P |e verfasserin |4 aut | |
| 700 | 1 | |a Parang, Bobak |e verfasserin |4 aut | |
| 700 | 1 | |a Keating, Cody E |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Joshua J |e verfasserin |4 aut | |
| 700 | 1 | |a Verriere, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Rachel E |e verfasserin |4 aut | |
| 700 | 1 | |a Piazuelo, M Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Bader, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Washington, M Kay |e verfasserin |4 aut | |
| 700 | 1 | |a Mittal, Mukul K |e verfasserin |4 aut | |
| 700 | 1 | |a Brand, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Gobert, Alain P |e verfasserin |4 aut | |
| 700 | 1 | |a Coburn, Lori A |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Keith T |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Christopher S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mucosal immunology |d 2008 |g 11(2018), 5 vom: 15. Sept., Seite 1363-1374 |w (DE-627)NLM185144039 |x 1935-3456 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2018 |g number:5 |g day:15 |g month:09 |g pages:1363-1374 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41385-018-0043-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2018 |e 5 |b 15 |c 09 |h 1363-1374 | ||